文献速递前列腺癌

前列腺健康指数(PHI)在不同前列腺癌患病率地区的作用:欧洲与亚洲需调整参考范围

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
PubMed 文献 · Eur Urol · 2018-11-02

该多中心研究比较了2488名亚洲与欧洲男性(PSA 2-20ng/ml)中PHI对前列腺癌的风险分层性能。亚洲男性在PHI>30时对高级别前列腺癌(HGPC)灵敏度达90%,可避免56%活检;欧洲男性需PHI>40,可避免40%活检。PHI优于PSA,但需采用人群特异性参考范围。

要点

  • 亚洲男性PHI>30对HGPC灵敏度90%,可避免56%活检。
  • 欧洲男性PHI>40对HGPC灵敏度90%,可避免40%活检。
  • PHI性能优于PSA,但需按人群调整参考范围。

核心结论

  • PHI对欧洲和亚洲男性均能有效进行前列腺癌风险分层,但应使用人群特异性PHI参考范围。

研究设计与样本

  • 多中心比较研究,纳入2488名PSA 2-20ng/ml且行PHI检测和经直肠超声引导活检的男性(1688亚洲、800欧洲,来自9个中心)。
  • 其中1652名PSA 2-10ng/ml且直肠指检正常者接受初次活检。

主要发现

  • 亚洲男性PHI<25、25-35、35-55、>55时HGPC诊断率分别为1.0%、1.9%、13%、30%。
  • 欧洲男性PHI<25、25-35、35-55、>55时HGPC诊断率分别为4.1%、4.3%、30%、34%。
  • AUC和DCA证实PHI优于PSA,重复活检(n=397)和PSA 10-20ng/ml(n=439)亚组亦获益。

关键数值与推荐

  • 亚洲男性以PHI>30为90%HGPC灵敏度阈值,可避免56%活检和33%Gleason 6前列腺癌诊断。
  • 欧洲男性以PHI>40为90%HGPC灵敏度阈值,可避免40%活检和31%Gleason 6前列腺癌诊断。

临床怎么用

  • 临床应采用人群特异性PHI参考范围进行前列腺癌风险分层,亚洲与欧洲男性阈值不同。
  • PHI可用于减少不必要活检和Gleason 6前列腺癌过度诊断,在重复活检及PSA 10-20ng/ml者中同样有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asians have a lower incidence of prostate cancer (PC). We compared the performance of the Prostate Health Index (PHI) for 2488 men in different ethnic groups (1688 Asian and 800 European men from 9 sites) with PSA 2-20ng/ml and PHI test and transrectal ultrasound-guided biopsy results available. Of these, 1652 men had PSA 2-10ng/ml and a normal digital rectal examination and underwent initial biopsy. The proportions of PC (Gleason ≥6) and higher-grade PC (HGPC, Gleason ≥7) across different PHI ranges were compared. The performance of PSA and PHI was compared using the area under the receiver operating characteristic curve (AUC) and decision curve analyses (DCA). Among Asian men, HGPC would be diagnosed in 1.0%, 1.9%, 13%, and 30% of men using PHI thresholds of <25, 25-35, 35-55, and >55, respectively. At 90% sensitivity for HGPC (PHI >30), 56% of biopsies and 33% of Gleason 6 PC diagnoses could have been avoided. Among European men, HGPC would be diagnosed in 4.1%, 4.3%, 30%, and 34% of men using PHI thresholds of <25, 25-35, 35-55, and >55, respectively. At 90% sensitivity for HGPC (PHI >40), 40% of biopsies and 31% of Gleason 6 PC diagnoses could have been avoided. AUC and DCA confirmed the benefit of PHI over PSA. The benefit of PHI was also seen at repeat biopsy (n=397) and for PSA 10-20ng/ml (n=439). PHI is effective in cancer risk stratification for both European and Asian men. However, population-specific PHI reference ranges should be used. PATIENT SUMMARY: The Prostate Health Index (PHI) blood test helps to identify individuals at higher risk of prostate cancer among Asian and European men, and could significantly reduce unnecessary biopsies and overdiagnosis of prostate cancer. Different PHI reference ranges should be used for different ethnic groups.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Ng CF, Semjonow A, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2018. PMID: 30396635. doi:10.1016/j.eururo.2018.10.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。